Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia

References

• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341(3):164-72
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340(17):1330-40
   PubMed Web of Science ®Google Scholar
• Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol 2003;532:121-40
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-30
   PubMed Web of Science ®Google Scholar
• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118(12):3123-7
   PubMed Web of Science ®Google Scholar
• Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Leukemia 2000;14(3):389-92
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98(10):3074-81
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004
   PubMed Web of Science ®Google Scholar
• Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010;47(4):354-61
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358-63
   PubMed Web of Science ®Google Scholar
• Parmar KK, King RS. Imatinib mesylate: a new pill for chronic myelogenous leukemia. Cancer Pract 2001;9(5):263-5
   PubMedGoogle Scholar
• Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 2001;28(5 Suppl 17):9-18
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56(1):100-4
   PubMed Web of Science ®Google Scholar
• Keller G, Schafhausen P, Brummendorf TH. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Hematol 2009;2(5):489-97
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Bosutinib tablets. Available from: www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm [Last accessed 17 March 2013]
   Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012;11(3):690-9
   PubMed Web of Science ®Google Scholar
• Boschelli DH. Exploitation of the 3-quinolinecarbonitrile template for SRC tyrosine kinase inhibitors. Curr Top Med Chem 2008;8(10):922-34
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Ye F, Wang YD, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001;44(23):3965-77
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23(3):477-85
   PubMed Web of Science ®Google Scholar
• Abbas R, Hug BA, Leister C, et al. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 2012;69(1):221-7
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567-76
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119(15):3403-12
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Khoury HJ, et al. Safety and efficacy of BOSUTINIB in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to IM and other TKIs: update from study SKI-200; Presented at the American Society of Clinical Oncology; 4–8 June, 2010; Chicago, IL, USA. Abstract 6509
   Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30(28):3486-92
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-61
   PubMed Web of Science ®Google Scholar
• Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective,multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010;95:224-31
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O’Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011;117(6):1822-7
   PubMed Web of Science ®Google Scholar